DMAC Overview

Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.

Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.

MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.

DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.

Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.

Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.

Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.

Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.

Company Participation: DiaMedica Therapeutics Inc. will have its President and CEO, Rick Pauls, participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025, where he will deliver a corporate presentation and engage in one-on-one investor meetings.

Presentation Details: The corporate presentation is scheduled for November 20, 2025, from 10:00 to 10:25 AM GMT.

Company Focus: DiaMedica is a clinical-stage biopharmaceutical company dedicated to developing treatments for serious conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke.

Lead Candidate: The company's lead candidate, DM199, is the first synthetic form of the KLK1 protein being clinically studied in the U.S. for acute ischemic stroke, with established therapeutic use in China.